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Background. Dengue is the most common arboviral infection of humans. There are currently no speciﬁc
treatments for dengue. Balapiravir is a prodrug of a nucleoside analogue (called R1479) and an inhibitor of hepa-
titis C virus replication in vivo.
Methods. We conducted in vitro experiments to determine the potency of balapiravir against dengue viruses
and then an exploratory, dose-escalating, randomized placebo-controlled trial in adult male patients with dengue
with <48 hours of fever.
Results. The clinical and laboratory adverse event proﬁle in patients receiving balapiravir at doses of 1500 mg
(n = 10) or 3000 mg (n = 22) orally for 5 days was similar to that of patients receiving placebo (n = 32), indicating
balapiravir was well tolerated. However, twice daily assessment of viremia and daily assessment of NS1 antigene-
mia indicated balapiravir did not measurably alter the kinetics of these virological markers, nor did it reduce the
fever clearance time. The kinetics of plasma cytokine concentrations and the whole blood transcriptional proﬁle
were also not attenuated by balapiravir treatment.
Conclusions. Although this trial, the ﬁrst of its kind in dengue, does not support balapiravir as a candidate
drug, it does establish a framework for antiviral treatment trials in dengue and provides the ﬁeld with a clinically
evaluated benchmark molecule.
Clinical Trials Registration. NCT01096576.
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Dengue is an acute illness caused by 1 of 4 single-
stranded positive-sense RNA viruses and is the
commonest arboviral infection of humans. In coun-
tries where dengue is endemic, the case burden strains
already fragile healthcare systems and has an econom-
ic cost [1, 2]. There are currently no licensed vaccines
for dengue (although late-stage trials are in progress),
and mosquito vector control has been mostly unsuc-
cessful or unsustainable.
Clinically apparent dengue manifests with a spec-
trum of symptoms. High fever, erythema, headache,
and myalgia are common symptoms, and laboratory
ﬁndings of leukopenia and mild thrombocytopenia are
typical. The critical phase occurs around the time of
defervescence, typically on days 4–6 of illness, during
which a transient capillary permeability syndrome
manifests in some patients. In children particularly,
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capillary permeability can be signiﬁcant enough to precipitate
life-threatening circulatory shock, called dengue shock syn-
drome (DSS). Treatment is supportive, and the mortality rate
for DSS in experienced hospital settings is <1% [2].
The magnitude of the early dengue virus (DENV) burden
in patients with dengue has been associated with overall clini-
cal outcome. For example, the early plasma viremia and/or
NS1 antigenemia levels in pediatric dengue patients who
develop clinically signiﬁcant capillary permeability are higher
than in patients without this complication [3–6]. The higher
antigenic burden in these patients is believed to trigger a
cascade of immunological events that promotes capillary per-
meability [7]. The association between high viral burdens in
the ﬁrst few days of illness and more severe outcomes has en-
couraged antiviral discovery efforts for dengue [8, 9], with the
rationale that a reduction of the viral burden should result in
a reduced incidence of severe complications and a lessening of
symptoms and illness duration.
Balapiravir is a prodrug of a nucleoside analogue
(4′-azidocytidine) called R1479 and was developed for the
treatment of chronic hepatitis C Virus (HCV) infection by
Hoffmann-La Roche. [10–12]. Monotherapy twice per day for
14 days reduced plasma HCV levels in a dose- and time-
dependent manner and was well-tolerated at doses up to 3000
mg in adult male patients [13]. However, the clinical develop-
ment of balapiravir for HCV infection was stopped when clin-
ical safety signals were detected in patients receiving extended
courses (2–3 months) of balapiravir therapy in conjunction
with pegylated interferon and ribavirin. Because HCV and
DENV possess RNA-dependent RNA polymerases that share
a similar overall architecture [14], we explored a new indica-
tion for balapiravir by testing the in vitro activity of R1479
against DENV. Subsequently, the safety, tolerability, and anti-
viral efﬁcacy of balapirivir in adult dengue patients were inves-
tigated in a clinical trial.
METHODS
Ethics Statement
The study was conducted according to International Confer-
ence on Harmonisation Good Clinical Practice guidelines. All
patients provided written informed consent. The trial protocol
was approved by the Oxford University Tropical Research
Ethical Committee and the Scientiﬁc and Ethical Committee
of the Ministry of Health, Vietnam. The trial was registered at
http://www.clinicaltrials.gov (NCT01096576).
Clinical Studies
Patient Enrollment
Adult men attending the outpatient department of the Hospi-
tal for Tropical Diseases, Ho Chi Minh City, Vietnam, who
presented with clinical suspicion of dengue conﬁrmed by
positive NS1 rapid test (NS1 STRIP, Bio-Rad) were invited to
participate in the study. The patient inclusion criteria for study
enrollment were (1) male patient aged 18–65 years, (2) history
or presence of fever (temperature, ≥38°C) coinciding with a
clinical suspicion of DENV infection and a positive NS1 rapid
test, (3) onset of symptoms <48 hours prior to initial dosing,
(4) and body mass index of 18–35. Two forms of contracep-
tion were required for male patients and their partners of
childbearing potential, and written informed consent was ob-
tained before any study-speciﬁc procedures were performed.
The patient exclusion criteria included (1) clinically signiﬁ-
cant abnormal laboratory test results which were deemed to
be unassociated with dengue infection, or alternatively were
diagnostic of dengue shock syndrome; (2) clinical evidence or
a history of clinically signiﬁcant respiratory, metabolic,
cardiac, renal, hepatic, gastrointestinal, hematological, neuro-
logical, psychiatric, or chronic disease; (3) positive test result
for human immunodeﬁciency virus (HIV) at screening; (4)
history of autoimmune or immune dysfunction disease; (5)
neutrophil count of <1500 cells/mm3, Haemoglobin (Hgb) con-
centration of <13 g/dL, or platelet count of <90 000 cells/mm3
at screening; (6) calculated creatinine clearance of <80 mL/
minutes; (7) hypertension or hypotension; (8) pulse pressure
of <20 mm Hg; (9) essential concomitant medication with the
exception of paracetamol; (10) positive test result for drugs of
abuse or alcohol; (11) recent participation in an investigational
drug or device study; and (12) not being a suitable candidate
for enrollment in the opinion of the investigator or sponsor.
Randomization, Masking, Dosing Schedule, and Dose
Escalation Cohorts
Randomization to treatment group was by computer-generated
randomization sequencing in blocks of 2. Balapiravir was formu-
lated in a 500-mg ﬁlm-coated tablet. The placebo consisted of
an identical looking tablet containing excipient only. All balapir-
avir and placebo tablets were provided by F. Hoffmann-La
Roche. Patients in cohort 1 (n = 20) received 1500 mg of balapir-
avir or an identical placebo orally every 12 hours for 5 days (10
doses). The decision to dose escalate (to 3000 mg) was made
after review of the partially unblinded group mean clinical and
laboratory data acquired from patients in cohort 1. Patients in
cohort 2 (n = 44) received 3000 mg of balapiravir or placebo
orally twice a day for 5 days (10 doses).
Safety Assessments
Eligible patients remained in clinic during a 7-day in-patient
period then returned for follow-up visits on study days 14, 28,
and 84. During the inpatient period, patient vital signs were
assessed every 6 hours and routine laboratory investigations
were performed daily or as clinically indicated. Safety and tol-
erability were monitored at regular intervals and included
physical examinations, vital signs, electrocardiograms, clinical
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laboratory assessments, incidence of clinical adverse events,
and concomitant medications. Any clinically signiﬁcant ab-
normal laboratory test results were followed up until resolved
or stabilized. A quality of life assessment, using a question-
naire and a visual analog scale, was implemented on study
days 1, 3, 5, 7, 14, 28, and 84.
Clinical Laboratory Investigations
Pharmacokinetics
Serum samples for pharmacokinetic investigations were col-
lected at time 0 (predose) and 2, 4, 8, and 12 hours postdose
on days 1 and 5. Pharmacokinetics parameters were calculated
using noncompartmental methods.
Virological and Immunological Measurements
Plasma samples were collected for virological and immunolog-
ical investigations every 12 hours, beginning immediately
before commencement of treatment, during the next 6 study
days and on one occasion on study day 7 and day 14 (virolog-
ical markers) or day 7 and day 28 (immunological markers).
Viremia was measured using a validated, internally controlled
reverse-transcription polymerase chain reaction assay in a Good
Clinical Laboratory Practice environment [15]. The limit of de-
tection was 357 copies/mL for DENV-1, 72 copies/mL for
DENV-2, 357 copies/mL for DENV-3, and 720 copies/mL for
DENV-4. The presence of NS1 in plasma was determined using
the Platelia NS1 assay (Bio-Rad) and was performed according
to the manufacturer’s instructions. Plasma cytokine levels (in-
terleukin 1β [IL-1β], IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70,
IL-13, interferon γ [IFN-γ], and tumor necrosis factor α
[TNF-α]) were measured using a Bio-Plex human cytokine
assay (Bio-Rad) and a multiplex array reader (Luminex
Systems, Bio-Plex workstation from Bio-Rad Laboratories) ac-
cording to the manufacturer’s instructions. Brieﬂy, 50-μL
plasma samples were incubated with monoclonal antibody
coupled beads. Complexes were washed twice, then incubated
with biotinylated detection antibodies and, ﬁnally, labeled
with streptavidin-phycoerythrin prior to analysis. Cytokine
concentrations in samples were calculated by use of recombi-
nant cytokines as standards and software provided by the
manufacturer (Bio-Plex Manager). All research samples (for
pharmacology, virology, and immunology) were collected and
processed in the laboratory within 1 hour of venupuncture.
All virological and immunological measurements and analyses
were performed by analysts who were blind to the treatment
assignment
Statistical Methods
All randomized patients in the study were analyzed according
to the intention-to-treat principle with 3 treatment groups:
1500 mg of balapiravir, 3000 mg of balapirivir, and placebo (com-
bining the patients in the placebo arms of both cohorts).
Key viremia endpoints of the study were as follows: area
under the log-transformed viremia curve (AUC) from ﬁrst
dose to the end of study day 7 (study hour 168), calculated on
the basis of the trapezoidal rule with values below the limit of
detection replaced by half of the detection limit; time to ﬁrst
viremia level of <1000 copies/mL until study day 7; and time
to the ﬁrst negative NS1 test result. Other predeﬁned key end-
points included fever clearance time, deﬁned as the time from
the start of treatment to the start of the ﬁrst 48-hour period
during which axillary temperature remained <37.5°C;
maximum hematocrit level; maximum percentage increase of
hematocrit level from baseline; platelet count nadir; and
lowest recorded quality of life score.
Time to event endpoints were compared between treatment
groups on the basis of Cox regression and continuous end-
points on the basis of linear regression. Analyses were adjusted
for the predose value of the respective endpoint; viremia and
NS1 endpoints were additionally adjusted for dengue serotype.
For all endpoints, we report P values of a trend test for a dose-
response relationship with treatment entered as a continuous
variable with values 0 (placebo), 1 (low-dose), and 2 (high-
dose) into the regression model.
The sample size of the study was determined by practical
and clinical considerations and not based on formal statistical
power calculations. However, we used simulation to post hoc
estimate the power of this trial to detect different effect sizes,
expressed as log10 viremia reductions per day due to active
drug. We assumed that the effect of high-dose drug is twice as
large as the low-dose effect and that the 32 recruited placebo
patients are representative of the entire target population. We
simulated drug effects of varying size on top of the observed
viremia proﬁles for these 32 patients and then used bootstrap
simulation to assess the power of an overall comparison of the
AUC of log10 viremia adjusted for serotype and baseline log10
viremia between study arms (trend test) and of a pairwise com-
parison of high dose versus placebo. According to these simula-
tions, the study would have had 80% power to detect a true
reduction of 0.25 log10 viremia per day (ie, one log10 reduction
over 4 days) in the high-dose group by both the trend test and
the pairwise comparison at the 2-sided 5% signiﬁcance level.
All analyses were performed with the statistical software R,
version 2.11.1 (R Foundation for Statistical Computing).
RESULTS
In Vitro Inhibition of DENV Replication by R1479 in Huh-7 Cells
R1479, the active nucleoside released from balapiravir, inhibit-
ed replication of DENV reference strains and clinical isolates
in Huh-7 cells with mean half maximal effective concentration
(EC50) values of 1.9–11 μM (Supplementary Table 1). Mean
values of median inhibitory concentration (IC50) for NITD008,
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a previously characterized nucleoside analogue polymerase in-
hibitor of DENV [16], were 0.1–0.6 μM (Supplementary
Table 1). R1479 was also active against DENV-1, DENV-2,
and DENV-4 (DENV-3 was not tested) in primary human
macrophages (mean EC50 range, 1.3–3.2 μM) and dendritic
cells (mean EC50 range, 5.2–6.0 μM; data not shown). These
data suggest R1479 has activity against DENV in vitro at EC50
concentrations pharmacologically attainable in adult humans
receiving ≥1500 mg of balapiravir twice per day [13].
Randomized, Double-Blind Placebo Controlled Trial of
Balapiravir in Adult Male Dengue Patients
A total of 64 adult patients with dengue were randomly as-
signed to receive either balapiravir or placebo within 48 hours
of symptom onset. Patients in cohort 1 were enrolled from 15
July 2010 through 10 September 2010 and received 1500 mg
of balapiravir (n = 10) or placebo (n = 10) orally twice a day
for 5 days (Figure 1). Patients in cohort 2 were enrolled from
1 October 2010 through 16 January 2011 and received 3000
mg of balapiravir (n = 22) or placebo (n = 22) orally twice a
day for 5 days (Figure 1). All enrolled patients completed their
schedule of study drug doses.
Baseline Characteristics of the Patients
The baseline characteristics of the intention-to-treat patient
population (n = 64 total) were similar in the balapiravir and
placebo groups (Table 1). The median duration of illness at
the time of commencing treatment was <40 hours for patients
in each arm of the study. DENV-1 and DENV-2 accounted
for the majority of infections (Table 1). Phylogenetic analyses
of genome-length virus sequences determined directly from
plasma samples from 40 (62.5%) of 64 patients identiﬁed the
DENV-1 viruses (n = 24 patients) as belonging to the geno-
type 1 lineage, the DENV-2 viruses (n = 11 patients) as be-
longing to the Asian 1 lineage, and DENV-3 viruses (n = 5
patients) as belonging to the genotype 2 lineage (data not
shown).
Intention-to-Treat Analysis of the Safety and Tolerability of
Balapiravir
A summary of the clinically signiﬁcant adverse events by treat-
ment arm is shown in Supplementary Table 2. No major clin-
ical or laboratory safety signals or signiﬁcant differences in
adverse event proﬁles between treatment groups were ob-
served. The range of adverse events reported was consistent
with the known clinical and laboratory features of dengue.
There were 4 reported serious adverse events (SAEs), 2 in the
placebo arm and 1 each in the 1500 mg and 3000 mg balapir-
avir arms (Supplementary Table 2). These SAEs were typical
of dengue (2 patients with prolonged thrombocytopenia, 1
patient with transient loss of visual acuity, and 1 patient with
narrowed pulse pressure). No SAEs were considered to be
Figure 1. Study enrollment and follow-up. The study enrolled 120 NS1-positive dengue patients who consented and were eligible to undergo screen-
ing against the inclusion and exclusion criteria; of these, 64 were eligible to continue into the study. The most common reasons for exclusion were low
creatinine clearance rates (53.6% of excluded cases), hepatitis B surface antigen positivity (23.2%), and abnormal serum creatinine level (17.9%). All
patients completed their dosage schedule of study drug.
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dose-related to balapiravir, nor was the dose of study drug
altered in response to these SAEs. All SAEs resolved.
Pharmacological Proﬁle and Antiviral Activity of Balapiravir
in Dengue
In the ﬁrst 12 hours of treatment, 95% of patients receiving
3000 mg of balapiravir had plasma maximum concentration
(Cmax) values of R1479 that were >6 μM (Table 2), a concentra-
tion that was inhibitory to DENV in vitro (Supplementary
Table 1). Values of Cmax were lower in patients receiving 1500
mg of balapiravir, but nonetheless were >6 μM in most patients
(Table 2). The C12 h values were 2.7–4.9 μM for 1500 mg and
2.1–15.7 μM for 3000 mg on day 1 of treatment. Similar dose-
dependent pharmacological ﬁndings were observed on study
day 5 (results not shown). Despite the pharmacological evi-
dence that balapiravir treatment elicited dose-dependent levels
of R1479 in vivo, there was no measurable effect on the prede-
ﬁned virological endpoints of time to clearance of viremia
(Table 3; Figure 2), time to clearance of NS1 antigenemia
(Table 3; Figure 3), or AUC (Table 3).
Balapiravir Effects on Clinical Signs and Routine Laboratory
Markers
Consistent with a lack of measurable antiviral activity, balapir-
avir treatment did not affect clinical signs or routine laboratory
ﬁndings (summary endpoint ﬁndings in Table 4). Thus, fever
clearance times (Supplementary Figure 1; Table 4) and changes
in hematological markers such as platelet count (Table 4) or
hematocrit level (Table 4) were not affected by balapiravir
treatment. Similarly, the kinetics of biochemical changes (liver
transaminase and coagulation marker level) were similar in
each of the treatment arms (Table 4). A quality of life score,
measured on a visual analogue scale, was also similar between
the treatment groups (Table 4). Collectively, these results indi-
cate a lack of measurable effect of balapiravir on these virologi-
cal, clinical, and routine laboratory markers.
Table 1. Baseline Characteristics of the Patient Population
Variable Placebo (n = 32) Balapiravir 1500 mg (n = 10) Balapiravir 3000 mg (n = 22)
Age, years 23 (21.0–28.0) 29.5 (23.5–32.0) 21 (20.0–31.3)
Weight, kg 60 (54.8–65.0) 64.5 (54.6–74.3) 58.5 (53.3–66.4)
Duration of illness at dosing, h 39.25 (36.11–44.89) 33.63 (27.5–45.13) 37.75 (30.85–43.38)
Oral temperature, °C 38.2 (37.6–39.1) 38.8 (38.1–39.3) 38.7 (38.2–39.0)
Serotype, no. of patients/plasma viremia level (range), log10 copies/mL
DENV-1 18/9.07 (4.63–10.52) 5/8.91 (7.50–10.63) 9/9.34 (8.05–9.86)
DENV-2 9/7.89 (6.51–9.58) 4/8.23 (7.57–9.14) 8/8.61 (8.03–9.46)
DENV-3 2/9.79 (9.62–9.96) 0 3/9.07 (8.79–9.17)
DENV-4 3/8.12 (6.12–8.37) 1/5.43 (5.43–5.43) 2/7.84 (7.58–8.10)
Serology, no. (%) of patients
Primary 4 (12) 1 (10) 0 (0)
Secondary 28 (88) 9 (90) 22 (100)
Data are median (interquartile range), unless otherwise specified.
Table 2. Pharmacokinetics of R1479 on Study Day 1
Parameter Tmax, h
a Cmax, μM
b Cmin, μM
b Tlast, h
c AUClast, h × μM
Cohort 1 (1500 mg twice daily)
Minimum 2 5.46 2.71 12 42.63
Median 4 16.54 3.56 12 110.56
Maximum 8 19.76 4.93 12 130.70
CV, % 49.1 30.5 21.3 … 55.81
Cohort 2 (3000 mg twice daily)
Minimum 2 8.78 2.14 12 70.05
Median 4 23.86 5.82 12 167.04
Maximum 12 90.60 15.73 12 608.09
CV, % 55.3 60 45.5 … 116.89
Abbreviations: AUClast, area under the log-transformed viremia curve; Cmax, maximum plasma concentration of R1479 on day 1; Cmin, minimum plasma
concentration of R1479 on day 1; CV, coefficient of variation Tlast, time since treatment when the last sample for pharmacokinetic measurement was collected;
Tmax, time after treatment when the maximum plasma concentration of R1479 was reached.
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Balapiravir Effects on the Host Immune Response and Virus
Sequence Diversity
Plasma concentrations of TNF-α, IFN-γ, IL-2, IL-4, IL-5, IL-6,
IL-10, IL-12p70, IL-13, and IL-1β were measured in serial
(daily) plasma samples during the inpatient period and at
follow-up (day 28). Concentrations of IFN-γ and IL-10 were
transiently elevated during the 48–96 hours after patient enroll-
ment, but this was independent of the treatment assignment.
Concentrations of TNF-α, IL-2, IL-4, IL-5, IL-6, IL-12p70,
IL-13, and IL-1β were low and did not increase by >2-fold
during the treatment period (data not shown). Changes in whole
blood gene transcript abundance in serial samples collected at
Table 3. Analysis of Predeﬁned Virological Endpoints in Patients Treated With Balapiravir or Placebo
Endpoint Placebo (n = 32) Low-dose Balapiravir (n = 10) High-dose Balapiravir (n = 22) P
AUC viremia, log10 copies/mL× d
a .623
Mean 32.78 34.49 32.56
Median (IQR) 32.19 (26.63–39.24) 29.63 (27.41–39.86) 31.98 (27.60–34.98)
Median time to first viremia level
of <1000 copies/mL, d (IQR)b
4 (3–6) 5 (4, NA) 4 (3–5) .476
Median time to first negative NS1
test result, d (IQR)b
4 (3–13) 3 (3–14) 4 (3–6) .852
a Values of area under the curve (AUC) of log10 viremia from day 1 first dose (hour 0) to the end of day 7 (hour 168) calculated with the trapezoidal rule. IQR,
interquartile range.
b Kaplan-Meier estimates based on data from the inpatient period only.
Figure 2. Viremia levels in balapiravir- and placebo-treated patients. Shown are serotype-stratiﬁed viremia levels, measured by reverse-transcription
polymerase chain reaction, in 12-hour spaced plasma samples, in patients treated with placebo, low-dose balapiravir, or high-dose balapiravir. The
colored lines in each graph represent smoothing lines derived from local polynomial regression ﬁtting to data from each treatment arm. The gray
background lines represent individual patient data. Abbreviations: DENV, dengue virus; R.arm, randomistation arm.
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baseline and on study days 4 and 28 were also monitored, but
there was no evidence of treatment-related effects on gene tran-
script abundance in subsequent samples (data not shown). Mu-
tation rates in virus genome sequences in serial plasma samples
from patients in the balapiravir and placebo arms were also not
signiﬁcantly different (data not shown). Collectively, these ex-
ploratory analyses are consistent with the predeﬁned trial clinical
and virological endpoints that suggest balapiravir did not mea-
surably alter the disease evolution of dengue.
DISCUSSION
The development of antiviral therapies for dengue is, along-
side vaccine development and vector control, a rational ap-
proach to reducing morbidity and preventing transmission. To
this end, here we show that the nucleoside analogue R1479
reduces dengue virus replication in human cells in vitro. Bala-
piravir, a prodrug of R1479, was also safe and well-tolerated in
adult dengue patients who received doses of 1500 mg or 3000
mg twice daily for 5 days. However, balapiravir treatment did
not improve virological, immunological, or clinical measures
of disease in patients who commenced treatment within the
ﬁrst 48 hours of their illness.
Balapiravir was well tolerated at both 1500 mg and 3000 mg
dosage schedules. The range of clinical and laboratory adverse
events observed in the balapiravir treatment arms were typical in
Vietnamese adults with dengue and not different from those seen
in the placebo arm. The rationale for stopping this exploratory
study after a total enrollment of 64 patients was that the dengue
transmission season was at an end and the number of patients
eligible for enrollment had dropped signiﬁcantly. Second, a
planned joint review of the clinical and laboratory data by the
sponsor and investigators led to the conclusion that balapiravir
was insufﬁciently potent to warrant further clinical investigation.
Balapiravir treatment in this study was not associated with
measurable changes in a range of virological, clinical, or im-
munological endpoints, despite evidence that the active
moiety R1479 had anti-DENV potency in vitro. Several possi-
bilities may explain this. First, the size of the patient cohorts
meant that only large effects could have been detected (see the
Methods section for further information on effect size).
Second, concentrations of R1479 in plasma may have been in-
sufﬁcient to inhibit DENV replication. Pharmacokinetic and
pharmacodynamic analyses of balapiravir in hepatitis C
showed a good correlation between exposure (measured as
AUC0–12 h or Cmin) and antiviral effect (measured as reduc-
tion in plasma HCV RNA level) [11]. In that study, dosing of
1500, 3000, or 4500 mg of balapiravir twice daily was associat-
ed with a dose-dependent increase in R1479 plasma exposure
and antiviral effect. A mean plasma trough level 3.5-fold
above the human serum adjusted HCV replicon EC50 was
achieved at the 1500 mg twice daily dose, and this ratio in-
creased to 4.9 and 7.8 in the 2 higher dose groups. In contrast,
no signiﬁcant antiviral effect was apparent at the lower dose of
500 mg twice daily, for which the mean plasma trough level
was similar to the HCV replicon EC50, even though Cmax was
>5-fold above the HCV replicon EC50 [11]. With a similar re-
lationship between exposure and antiviral effect in DENV in-
fection, mean Cmin concentrations exceeding 6.7–39 µM or
Cmax concentrations exceeding 25–145 µM may be needed for
the observation of antiviral effects of R1479 on DENV. This
would argue for higher or more frequent doses of balapiravir.
Dosing of 4500 mg twice daily of balapiravir achieved mean
Cmin of 21 µM and mean Cmax of 88 µM in HCV-infected
persons [11]. However, this more aggressive strategy might
also be accompanied by increased likelihood of drug-related
adverse events as seen previously with short-course monother-
apy (4500 mg of balapiravir twice a day in HCV-infected pa-
tients) [13]. Third, the antiviral effect of R1479 is dependent
on phosphorylation to the DENV polymerase inhibitor R1479
triphosphate. Phosphorylation efﬁciency can differ between
cell types, and R1479 may not be efﬁciently phosphorylated in
Figure 3. Kaplan-Meier plot of NS1 antigenemia over time in balapira-
vir- and placebo-treated patients. Shown are the proportions of patients
over time that tested NS1-positive in serial plasma samples collected daily
from baseline (pretreatment) to study day 7, and again on study day 14.
There was no signiﬁcant difference in time to clearance of NS1 antigene-
mia between treatment groups. Abbreviation: R.arm, randomistation arm.
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the primary DENV target cells in humans. Finally, although
the median duration of illness history was <40 hours in all
treatment groups, it is possible that the timing of treatment
was too late in this patient population to demonstrate a
marked antiviral effect above the level that the host adaptive
immune response achieves. Indeed, it is striking that decreases
in viremia were observed in the majority of patients within 24
hours of enrollment irrespective of the treatment assignment
(Figure 2). This underlines the imperative of early diagnosis
and treatment with antiviral candidates.
New therapies may require certain properties to be success-
ful for the treatment of an acute infection such as dengue. An-
tiviral agents must be effective immediately to rapidly control
viral replication. Problems of distribution, active metabolite
formation, or protein binding may limit the effective response
time. Consideration of prophylactic treatment at the ﬁrst indi-
cation of symptoms may be needed to successfully impede
viremia, but it will require a compound with a robust safety
proﬁle. Although the current study did not furnish evidence
that balapiravir at the doses tested is a candidate drug for
dengue, it is hoped that this marks the beginning of an inten-
sive period of clinical research on dengue therapeutics.
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Table 4. Analysis of Predeﬁned Clinical and Routine Laboratory Endpoints
Key Endpoint Placebo (n = 32)
Low-dose Balapiravir
(n = 10)
High-dose Balapiravir
(n = 22) P
Median fever clearance time, d (IQR)a 3 (3–4) 3 (2–4) 3 (2–4) .286
Maximum recorded hematocrit level, %
Mean 46.0 46.7 44.6 .102
Median (IQR) 45.9 (44.0–47.3) 45.8 (43.8–49.3) 45.1 (41.8–46.1)
Maximum percentage increase of hematocrit level, %
Mean 7.0 11.5 2.6 .131
Median (IQR) 6.7 (0.8–10.0) 11.8 (3.1–15.3) 1.2 (−4.1–9.2)
Minimum platelet count, 109 cells/L
Mean 52.6 26.3 54.4 .886
Median (IQR) 47.5 (28.5–64.0) 23 (16.5–33.0) 52 (25.5–64.8)
Maximum INR
Mean 1.23 1.17 1.27 .819
Median (IQR) 1.15 (1.08–1.26) 1.16 (1.05–1.26) 1.17 (1.09–1.22)
Maximum aPTT, s
Mean 42.2 41.3 41.8 .962
Median (IQR) 40.7 (39.0, 44.5) 40.6 (39.6–43.1) 41.8 (38.3–44.1)
Minimum fibrinogen level, g/L
Mean 1.92 1.94 1.88 .902
Median (IQR) 1.99 (1.63–2.14) 2.08 (1.68–2.25) 1.86 (1.60–2.03)
Maximum AST level, IU/L
Mean 134.0 143.6 118.4 .646
Median (IQR) 97.0 (70.0–191.5) 157.5 (116.5–171.5) 108.0 (45.0–151.5)
Maximum ALT level, IU/L
Mean 111.6 96.3 75.2 .125
Median (IQR) 87.5 (53.3–149.0) 97.5 (58.0–128.8) 68.5 (33.3–104.5)
Minimum quality of life scorea
Mean 76.5 78.3 74.45 .478
Median (IQR) 84.5 (69.8–89.3) 77.0 (69.8–89.0) 77.5 (67.8–82.0)
Abbreviations: ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; IQR, interquartile range; INR,
international normalized ratio.
a Visual analogue scale: 0 is the worst imaginable health state the patient can think of, 100 is the best imaginable health state.
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